Lomustine — Drug Intelligence | 10 EU Trials

Filter these 10 trials by condition, phase, country and more.

Open in Search →

10 Registered trials

4 Recruiting

3 Completed trials

10 Sponsors

12 Countries

Phase III

Phase II/III

Phase II

Phase III: 4 Phase II/III: 1 Phase II: 5

Indications tested

Medulloblastoma 3 Glioblastoma 1 Malignant glioma 1 Glioma 1 Glioblastoma multiforme 1

Sponsors using this IMP

Assistance Publique Hopitaux De Paris 1 Azienda Ospedaliera Universitaria Meyer IRCCS 1 Cns Pharmaceuticals Inc. 1 European Organisation For Research And Treatment Of Cancer 1 Philogen S.p.A. 1 Rigshospitalet 1 Telix Pharmaceuticals (Innovations) Pty Limited 1 The University Of Birmingham 1 Universitaetsklinikum Heidelberg AöR 1 University Medical Center Hamburg-Eppendorf 1

All trials

10 total

A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence Not authorised

2024-515609-25-00 Phase II 2 countries Philogen S.p.A.
Multisite open-label randomized phase II clinical trial in newly diagnosed glioblastoma treated by concurrent TemoRadiation and adjuvant tem… Pending

2024-511880-27-00 Phase II 2 countries Assistance Publique Hopitaux De Paris
SIOP PNET 5 medulloblastoma Pending

2024-513724-42-00 Phase II/III 10 countries University Medical Center Hamburg-Eppendorf
A Phase III Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients with Recurrent Glioblastoma Recruiting

2025-521785-10-00 Phase III 3 countries Telix Pharmaceuticals (Innovations) Pty Limited
A randomized phase III trial with lomustine versus lomustine and bevacizumab for patients with recurrent glioblastoma Recruiting

2024-519437-27-02 Phase III 1 country Rigshospitalet
SIOP-HRMB: An international prospective trial on clinically high-risk medulloblastoma (HR-MB) in patients older than 3 years. Recruiting

2024-510578-25-00 Phase III 10 countries The University Of Birmingham
Improvement of functional outcome for patients with newly diagnosed grade 2 or 3 glioma with co-deletion of 1p/19q - IMPROVE CODEL: the NOA-… Recruiting

2024-510616-73-00 Phase III 1 country Universitaetsklinikum Heidelberg AöR
An interventional, open-label, Phase II study, to evaluate safety and efficacy of standard and high-dose chemotherapy associated with cranio… Ended

2024-518964-11-01 Phase II 1 country Azienda Ospedaliera Universitaria Meyer IRCCS
Trial investigating a personalized treatment, based on age and tumor characteristics , of newly diagnosed medullablastoma in patients that a… Ended

2023-506193-12-00 Phase II 1 country European Organisation For Research And Treatment Of Cancer
A study of Berubicin in Adult Patients with Recurrent Glioblastoma Multiforme Ended

2024-517660-27-00 Phase II 3 countries Cns Pharmaceuticals Inc.

Showing 1–10 of 10 trials

← All drugs A–Z